Medical Korea Brand Proclamation Ceremony & Symposium
8.10.2020 15:00:00 EEST | Business Wire | Press release
Since 2009, Korea has been promoting its medical competitiveness, and established a national medical brand titled “Smart Care, Medical Korea”, to represent the excellence of Korea’s medical services.
From 2009 to 2019, more than 2.76 million visitors from 190 countries around the world visited Korea to experience medical services. Also, Korea has provided a medical training program for international medical professionals from 31 different countries, sharing and expanding Korean medical system and resources across the world.
These efforts have been internationally recognized and received the “Health and Medical Tourism: Destination of the Year” award twice consecutively in 2018 and 2019 from the IMTJ Medical Travel Awards, a prestigious global medical tourism awards ceremony. In recognition of improving the reputation of Korea’s medical brands across the world and continuous dedication to enhancing healthcare, Korea was also awarded the “Porter Prize for Excellence in CSV”, named after a world-renowned business administration scholar, Michael E. Porter.
To address the recent global pandemic with the COVID-19, Medical Korea has renewed its brand to “Medical Korea, Where Your Days Begin Again” which emphasizes the humanitarian value of regaining the everyday life. Under this brand, Medical Korea will continue to stay at the forefront of achieving health and wellness for people around the world.
Korea Health Industry Development Institute (KHIDI) will announce the renewal of its brand and set a new direction for the healthcare industry during the COVID-19 era at the “Medical Korea Brand Proclamation Ceremony & Symposium”, held by the Ministry of Health and Welfare and organized by KHIDI, on October 14, 2020 (11:00~17:10, GMT+9).
The event will start with the keynote speech by Dr. Jerome Kim, Director General of the International Vaccine Institute (IVI), followed by presentations by Dr. Andrew Trister, Deputy Director of Digital Health and Innovation at Bill & Melinda Gates Foundation, and Hyung-gyoun (Harris) Byun, Vice President of KT. The presentations will shed light on the impact of the 4th industrial revolution in the medical service industry and will be aired live online. (https://www.medical-korea.org/eng/symposium/symposium.do)
About KHIDI
The Korea Health Industry Development Institute is a government-affiliated institution which provides the systematic and professional support for the improvement of public health and enhancement of the international competitiveness in the health industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005268/en/
Contact information
W Medical Strategy Group
US Representative
wgroup@wmedical.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a
Zayed Sustainability Prize Closes 2027 Submissions with Strong Global Participation13.7.2026 12:48:00 EEST | Press release
The Zayed Sustainability Prize, the UAE’s pioneering award for innovative solutions to global challenges, has officially closed submissions for its 2027 awards cycle, receiving an unprecedented 10,233 entries from 177 countries across its six categories of Health, Food, Energy, Water, Climate Action and Global High Schools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713519403/en/ Zayed Sustainability Prize Closes 2027 Submissions with Strong Global Participation (Photo: AETOSWire) Now in its 18th year, the Prize continues to attract a diverse and growing pool of small and medium-sized enterprises, nonprofit organisations and high schools developing solutions that improve lives, particularly in vulnerable and underserved communities. This year’s submissions point to a growing emphasis on resilience, adaptability and systems-level impact. Across regions, applicants are addressing complex global challenges through practi
Ant Group Open-Sources SingGuard-NSFA to Establish New Security Paradigms for Autonomous AI Agents13.7.2026 12:01:00 EEST | Press release
Ant Group’s AI Security Lab today announced the open-source release of SingGuard-NSFA, a specialized security guardrail framework designed specifically for autonomous AI agents. The framework secures agentic AI systems against operational threats like prompt injection, addressing critical vulnerabilities as AI transitions from passive content generation to active, autonomous execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712722454/en/ As AI agents rapidly move from research labs to business scenarios, the security landscape has fundamentally shifted. The explosive global adoption of open-source agent frameworks like OpenClaw, celebrated for their "one-click deployment" and "full-stack autonomy", has simultaneously exposed significant operational risks, including permission escalation and prompt injection. Industry frameworks, including the OWASP (Open Web Application Security Project) Top 10 for Agentic Applica
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types13.7.2026 11:00:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris. Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability to prevent or reduce the frequency of bleeding episodes. Latarcibart is in pivotal Phase 3 development for patients with VWD, the most common inherited bleeding disorder. If approved, latarcibart has the potential to be the first, once monthly subcutaneous prophylactic therapy for patients with VWD, offering an important alternative to the frequent intravenous infusions of replacement factor concentrates commonly used in the prophylactic setting today. Gi
Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™13.7.2026 11:00:00 EEST | Press release
Demand for technology services in Europe continued to accelerate in the second quarter, as the region increasingly turns to managed services to reduce costs and cloud services to meet AI objectives, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows second-quarter ACV for the combined market (both managed services and cloud-based as-a-service) soared 46 percent—its largest growth in eight years—to US $13.0 billion. The latest quarter adds to a string of three straight quarters in which growth has averaged 33 percent. “Europe has become the fastest-growing region for technology services, fueled not only by an increasing demand for AI, but for managed services, which acts as a cost-savings lever to help fund AI ambitions and continued digital
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom